Hornbeck Offshore Enters Into Multiple Deepwater Services Agreements

HOUSTON and COVINGTON, La., Nov. 2, 2026 /PRNewswire/ -- Hornbeck Offshore Services, Inc. ("Hornbeck") (NYSE: HOS), a premier integrated offshore services company, today announced that it has entered into multiple agreements with Shell Offshore Inc. ("Shell") to provide services in the U.S. Gulf of America. Under these agreements, Hornbeck will provide a comprehensive range of integrated deepwater services including riser based well intervention, riserless well intervention stimulation support, and marine transportation.

In furtherance of the agreements, Hornbeck expects to deploy:

a. A technologically advanced riser-based Well Intervention Vessel combined with an Intervention Riser System (IRS), Remotely Operated Vehicles (ROVs), Project Management and Engineering services.

b. A high-specification Multi-Purpose Support Vessel combined with ROVs, Project Management and Engineering services.

c. Deepwater Jones Act-compliant Offshore Supply Vessel(s) supporting the Well Intervention and Multi-Purpose Support Vessel.

Operations are scheduled to commence in 2027, with the riser based Well Intervention Vessel and support vessel contracted for five years.

Todd M. Hornbeck, Hornbeck's President and CEO commented, "We are excited to expand our longstanding relationship with Shell. We look forward to delivering integrated services through a unique combination of high-specification assets in the deepwater basins of the U.S. Gulf of America. This exemplifies the breadth and depth of what the complementary combination of Hornbeck Offshore and Helix Energy Solutions can now deliver to the market."

About Hornbeck Offshore Services

Hornbeck is a global offshore services leader, providing innovative and integrated marine and subsea solutions to customers across the deepwater oilfield, defense, and renewables industries.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present or historical fact included in this press release are forward-looking statements. Words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "should," "will" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words, and the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements include, but are not limited to, statements regarding: the agreements, the equipment and services thereunder and the parties thereto. Forward looking statements are based on current expectations and assumptions and involve known and unknown risks, uncertainties and other important factors, many of which are beyond the company's control, including, but not limited to, risks related to actions by governments, regulatory authorities, customers, suppliers and partners; market conditions; demand for services; the performance of contracts by suppliers, customers and partners; operating hazards and delays, which includes delays in delivery, chartering or customer acceptance of assets or terms of their acceptance; complexities of global political and economic developments; the impact of general economic conditions, including inflation, on economic activity and on the company's operations; the general volatility of oil and natural gas prices and cyclicality of the oil and gas industry; and other risks described from time to time in the company's filings with the SEC. Forward-looking statements speak only as of the date they are made. The forward-looking statements in this press release are based upon information available to the company as of the date of this press release and, while the company believes such information forms a reasonable basis for such statements, these statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Actual outcomes may vary materially from those described in these statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the company's filings with the SEC. The company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements, other than as may be required by applicable law or regulation.

Contacts:

Potter Adams

Executive Vice President and CFO

985-727-6815

[email protected]

Ken Dennard / Alex Harp

Dennard Lascar Investor Relations

713-529-6600

[email protected]

SOURCE Hornbeck Offshore Services, Inc.

Share this article

LTL Supply Rebrands to Value Added Distributors

DE PERE, Wis., Nov. 2, 2026 /PRNewswire/ -- LTL Supply, a leading supplier of wire harnesses and electrical supplies, announced today their rebrand to Value Added Distributors. The rebrand marks the final step in LTL Supply's integration to Value Added Distributors, which acquired the company in November 2025. Operating under one name will present a clear brand name and result in an expanded range of products & services to customers.

"For more than 40 years, LTL Supply has built a reputation of providing high-quality wire harnesses and electrical supplies to customers". David Burt, VP of Sales at VAD said. "Since the acquisition, our teams have been working closely to align operations, combine resources and set shared goals, all with our customers' needs at the forefront. That work ensures a seamless transition today and positions us to deliver more products, resources and support in the years ahead."

LTL Supply's experienced customer service team, service levels and product portfolio will remain unchanged. The company's commitment to quality will continue to be their primary focus and every wire harness that leaves their facility will undergo stringent quality testing to ensure it is of the highest standard. The company will also continue to provide battery cable assemblies, main electrical centers and control panels engineered for dependable, long-term performance.

"Officially becoming Value Added Distributors is an exciting step for our team." Katie Cegelski, General Manager, LTL Supply said. "Our customers will continue to work with the same people they know and trust, now backed by the added resources, broader product offering and expanded capabilities. While our name is changing, the values that built our business over the past 40 years will continue to guide everything we do."

All future communications will come from Value Added Distributors. Please visit the company's website for more information.

About Value Added Distributors:

Since 1995, Value Added Distributors (VAD) has built its reputation on expertise, reliable products and value-added solutions. As a Parker Hannifin Certified Hose Assembly distributor, the company combines decades of application expertise with value-added distribution to help customers solve fluid power challenges and improve operational efficiency.

SOURCE Value Added Distributors

Share this article

Q-Ball Intelligence launches to bring Predictive Intelligence into the AI era

19 years of predictive research, backed by a nine-year real-world investment record returning 235.19%

SAN FRANCISCO, Nov. 2, 2026 /PRNewswire/ -- Q-Ball Intelligence today announces its launch as a new AI-native Predictive Intelligence venture, building on nearly two decades of research and practical applications dating back to 2007.

The company is developing a new generation of artificial intelligence capable of identifying emerging signals, recognising patterns and anticipating future developments moving beyond analysing what has happened to understanding what is likely to happen next.

The research behind Q-Ball has already been applied in practice. Between 17 February 2016 and 17 February 2025, a Q-Ball-informed investment portfolio delivered a cumulative return of 235.19%.

For comparison, the portfolio analysis shows returns of 129.86% for OMX Stockholm All-Share Gross Index (OMXSGI), representing the broader Swedish equity market, and 106.55% for OMX Stockholm 30 Index (OMXS30) over the same period. This represents an outperformance of 105.33 and 128.64 percentage points respectively.

The nine-year investment record provides a tangible example of the practical application of predictive research developed under the leadership of Assistant Professor Peter Majanen. It represents an actual investment portfolio record rather than a simulated backtest.

From analysing information to anticipating change

Most analytical systems are designed to process information, identify historical trends and explain developments that have already taken place.

Q-Ball is pursuing a different objective: recognising the signals and changing expectations that may reveal what comes next.

Its predictive methodology connects information, expectations, emerging patterns and momentum with potential catalysts and future outcomes. The objective is to translate complex information into structured, measurable forecasts.

The underlying research originated in 2007 and has evolved through nearly two decades of development and practical application. Q-Ball Intelligence represents the next stage: transforming this foundation into a scalable technology platform designed for international markets.

Building a new Predictive Intelligence platform

Q-Ball is developing an AI-native platform designed to identify relevant signals, assess emerging developments, generate structured forecasts and measure predictions against actual outcomes.

The company's approach places particular emphasis on understanding changes in expectations and behaviour, rather than relying exclusively on historical data and conventional trend analysis.

By combining predictive methodology with AI-driven analysis, Q-Ball aims to create technology that helps organisations and individuals anticipate change, assess opportunities and make better-informed decisions.

An important part of the development philosophy is accountability: predictions should be structured, time-stamped and evaluated against what actually happens. This creates a foundation for continuous measurement, refinement and learning.

Applications across multiple markets

Q-Ball Intelligence is developing its technology for institutional and commercial customers, with additional applications across financial markets, sports and gaming.

Initial areas of focus include:

Enterprise Predictive Intelligence helping organisations anticipate market developments, changing conditions, emerging risks and strategic opportunities.

Financial Markets developing predictive intelligence for equities and financial markets, identifying emerging patterns and assessing the probability of potential market developments.

Sports and Gaming applying predictive models to sporting outcomes, competitive environments and gaming-related markets.

The company is building these applications on a shared predictive foundation, extending its core intelligence capabilities across different markets and customer segments.

A new chapter for predictive intelligence

"Prediction is not about knowing the future. It is about understanding the present well enough to recognize what the future is beginning to become," says Peter Majanen, Founder and Chief Predictive Intelligence Architect.

Q-Ball Intelligence aims to establish Predictive Intelligence as a distinct category within the evolving AI landscape moving beyond systems that primarily describe the world towards technology designed to anticipate how it may change.

With research foundations dating back to 2007, the company now enters a new phase focused on technology development, commercialisation and international expansion.

Q-Ball Intelligence Predicting What Comes Next.

About Q-Ball Intelligence

Q-Ball Intelligence is an AI-native Predictive Intelligence venture developing technology designed to identify emerging signals, recognise patterns and anticipate future developments.

Its foundations combine predictive research, proprietary analytical methodology and practical applications developed since 2007. The company is focused on transforming this foundation into a scalable predictive intelligence platform for institutional, commercial and consumer applications.

Website: www.qballintel.com

Press contact:

Richard Sjoberg

Q-Ball Intelligence

[email protected]

www.qballintel.com

Historical performance disclosure: The portfolio return of 235.19% relates to the period 17 February 2016 to 17 February 2025. Benchmark figures are based on Avanza data for OMX Stockholm All-Share Gross Index (OMXSGI) and OMX Stockholm 30 Index (OMXS30) over the same period. Historical performance is not indicative of future results. The historical portfolio performance should not be interpreted as performance generated by the new Q-Ball Intelligence platform or as a guarantee of future investment outcomes.

SOURCE Q-Ball Intelligence

Share this article

Next step: extending the model into a dynamic, AI-supported digital twin under the U.S. Department of Energy's Genesis Mission

TORONTO, Nov. 2, 2026 /PRNewswire/ -- Aclara Resources Inc. ("Aclara" or the "Company") (TSX: ARA) is pleased to announce the successful completion of its first Cooperative Research and Development Agreement ("CRADA") with Argonne National Laboratory ("Argonne"), a U.S. Department of Energy ("DOE") national laboratory. Under the CRADA, signed on January 13, 2026, Aclara and Argonne developed and validated a steady-state model of the rare earth separation process for Project Dynamo, Aclara's planned rare earth separation facility in Vinton, Louisiana. The model was calibrated and validated using operating data from Aclara's rare earth separation demonstration plant at the Virginia Tech Corporate Research Center in Blacksburg, Virginia.

Aclara Technologies Inc., a wholly-owned subsidiary of the Company, together with Argonne and Virginia Tech, were selected for Phase I of the DOE's Genesis Mission, as announced on July 23, 2026. The team intends to extend the model to simulate the plant's dynamic behavior and to build on it an artificial intelligence agent that supports plant operators in their day-to-day decision-making. The objective is a faster, more stable and lower-cost separation operation. Phase I is subject to execution of the award agreement with the DOE, which is currently being finalized.

CRADA Highlights

Separation is arguably the most complex process technology in the rare earth value chain and the most geographically concentrated, with China controlling approximately 90% of global processing capacity. Project Dynamo's separation plant is designed as a network of 478 interconnected mixer-settler stages in which the individual rare earth elements are separated by solvent extraction. The chemical equilibrium of each stage is connected with the others as the aqueous and organic phases are in counter-current flow. A change in operating conditions at any point in the process shifts the equilibrium of the surrounding stages and propagates across the entire circuit. Even a minor adjustment to an acid or base flow rate can have this effect. This makes separation plants challenging to operate. Adjustments in process conditions cannot be made in isolation as they will impact the entire circuit. The industry has historically relied on operator experience accumulated over years to understand the impact of changes. In practice, this leads to conservative operation: operators make small, infrequent adjustments to avoid upsetting the equilibrium of the circuit, which slows ramp-up and extends the time needed to reach target purities.

Under the CRADA, the Aclara and Argonne teams built a steady-state model of the separation circuit capable of predicting the concentration of each rare earth element in every stage. The model was calibrated against the complete set of demonstration plant operating data and chemical assays. This established a validated baseline to launch process optimization and operating scenario analysis. The model allows Aclara to simulate changes in operating conditions before implementing them in the plant. This capability is expected to reduce the technical risk of Project Dynamo by predicting the effect of process changes on recovery and purity, by quantifying the impact of feed variability and by facilitating the optimization of ramp-up conditions.

Genesis Mission: From Validated Model to AI-Supported Digital Twin

The Genesis Mission is a national initiative led by the DOE to apply artificial intelligence and advanced computing to priority challenges in energy, scientific discovery and national security, mobilizing the DOE's 17 national laboratories together with industry and academia.

The model developed under the CRADA describes the separation process at steady state. Phase I of the Genesis Mission is expected to extend it to simulate how the circuit responds in time to operational disturbances, such as a change in feed composition or a deviation in a flow rate. Modelling this behavior across hundreds of coupled stages requires computational resources far beyond those of conventional process engineering tools, and the program is expected to draw on Argonne's high-performance computing infrastructure for this purpose.

The second step of Phase I is an artificial intelligence agent that uses the dynamic model to deliver operating recommendations to plant operators, moving optimization from periodic, conservative adjustments based on experience to more frequent, data-driven decisions. The objectives are to reduce the human error inherent in operating a circuit of this complexity on the basis of experience alone, shorten the time required to achieve target purities, lower operating costs through more efficient use of reagents, and absorb feed variability. These improvements are expected to shorten the ramp-up of Project Dynamo and accelerate the production of separated rare earth oxides.

Following completion of Phase I, the Company plans to apply to Phase II of the Genesis Mission, with the objective of deploying the digital twin in the plant connected to the plant's sensors and actuators such that the operating conditions can be adjusted automatically. This is expected to result in a more stable separation operation with even lower variability and increased overall recovery and purity. Any Phase II award is subject to the DOE's evaluation process, and there can be no assurance that an application will be submitted or that any award will be made.

Ramón Barúa, Chief Executive Officer of Aclara, commented:

"This is a major milestone for Aclara. Rare earth separation is the most technically complex and strategically important step in the value chain. Together with Argonne, we have developed a validated modelling tool, laying the foundation for dynamic, AI-driven optimization under the DOE's Genesis Mission. This technology has the potential to accelerate Project Dynamo's ramp-up, improve efficiency and substantially reduce operating risk. It demonstrates our commitment to making technology a key enabler as we build a reliable, sustainable and geopolitically diversified supply of critical materials."

Claus Daniel, Associate Laboratory Director, Argonne National Laboratory, commented:

"Building a secure domestic supply of rare earths requires closing the gap between promising technologies and reliable industrial operations. Our collaboration with Aclara brings Argonne's expertise in process modelling and scale-up to one of the most complex steps in that supply chain. This work provides a foundation for applying advanced computing and super intelligence to help industry reduce the time, cost and risk of bringing new U.S. critical materials capacity into production."

About Argonne National Laboratory

Argonne National Laboratory is a multidisciplinary DOE national laboratory near Chicago that conducts leading-edge basic and applied research across a broad range of scientific disciplines to address pressing national challenges in science and technology. Argonne is managed by UChicago Argonne, LLC for the DOE's Office of Science.

About Project Dynamo

Project Dynamo is Aclara's planned rare earth separation facility in Vinton, Louisiana, and a key component of the Company's vertically integrated rare earth strategy. The facility is being designed to process rare earth feedstock from Aclara's mineral resources and produce separated rare earth oxides in the United States.

About Aclara

Aclara Resources Inc. (TSX: ARA), a Toronto Stock Exchange-listed company, is focused on building a vertically integrated supply chain for rare earth alloys used in permanent magnets, as well as high-purity rare earth oxides, including yttrium and gadolinium, for power generation, aerospace and other high-performance applications. This strategy is supported by Aclara's development of rare earth mineral resources hosted in ionic clay deposits, which contain high concentrations of the scarce heavy rare earths, providing the Company with a long-term, reliable source of these critical materials. The Company's rare earth mineral resource development projects include the Carina Project in the State of Goiás, Brazil as its flagship project and the Penco Module in the BiobÃo Region of Chile. Both projects feature Aclara's patented technology named Circular Mineral Harvesting, which offers a sustainable and energy-efficient extraction process for rare earths from ionic clay deposits. The Circular Mineral Harvesting process has been designed to minimize the water consumption and overall environmental impact through recycling and circular economy principles. Through its wholly-owned subsidiary, Aclara Technologies Inc., the Company is further enhancing its product value by developing a rare earth separation plant in the United States. This facility will process super pure rare earth carbonate sourced from Aclara's mineral resource projects, separating it into individual rare earth oxides. Additionally, Aclara, through a joint venture with CAP S.A., is advancing its alloy-making capabilities to convert these refined oxides into the alloys needed for fabricating permanent magnets. This joint venture leverages CAP S.A.'s extensive expertise in metal refining and special ferro-alloyed steels. Beyond the Carina Project and the Penco Module, Aclara is committed to expanding its mineral resource portfolio by exploring greenfield opportunities and further developing projects within its existing concessions in Brazil, Chile and Peru, aiming to increase future production of heavy rare earths.

McKay Brothers and Relativity Networks Partner to Expand Hollow Core Networks for Financial Markets and Compute

Initial focus on key New Jersey financial market venues with dedicated fiber IRUs and connectivity services from 10 to 400 Gbps

CHICAGO, Ill. and ORLANDO, Fla., Nov. 2, 2026 /PRNewswire/ -- McKay Brothers and Relativity Networks today announced a partnership to develop and expand hollow-core fiber networks for financial services and growing compute demand. The companies will initially focus on interconnecting key financial market venues in New Jersey, with expansion into other markets.

McKay has selected and purchased Relativity's ChronoCore⢠anti-resonant hollow-core fiber for commercial deployment in its New Jersey networks. The companies are combining Relativity's technology and roadmap with McKay's experience developing and operating networks. The design includes branches for high-capacity, low-latency interconnection to data center development projects near key financial corridors, where customers are developing inference and training infrastructure.

McKay is offering long-term indefeasible rights of use (IRUs) on dedicated hollow-core fiber pairs for the networks. It will also offer traditional connectivity services from 10 Gbps to 400 Gbps for customers with a range of requirements.

"We have worked with successive generations of hollow-core fiber for nearly a decade. Relativity offers the best technical solution we have evaluated for the networks we want to build," said Tim Boyle, Chief Operating Officer of McKay Brothers. "For critical U.S. market infrastructure, IP provenance and security of supply matter alongside performance. Relativity's strong U.S. patent portfolio and roadmap, enabled by Prysmian's proprietary fiber and cable production, give us the confidence to invest for the long term. New Jersey is just the start."

ChronoCore's low dispersion, coupled with optimal route design, supports more capacity and longer reach with fewer active optical components. Reducing intermediate regeneration lowers power and real estate requirements. McKay is designing the networks to reduce the total cost of carrying data, deliver lower latency and make both benefits available to all market participants.

"McKay brings nearly a decade of experience putting hollow-core fiber to work in demanding environments, from data centers and outside plant to towers and integrated fiber-wireless networks," said Jason Eichenholz, Founder and CEO of Relativity Networks. "That experience spans the routes and real estate needed to build and operate networks. That makes McKay the right partner to develop this opportunity with us and serve the growing infrastructure needs of AI inference. McKay's partnership and purchase mark an important commercial milestone for Relativity and provide a foundation for expanding financial-market networks and advancing the network infrastructure of the AI economy together."

"The intersection of power availability and real estate determines where compute gets built," Boyle added. "Our aim is to connect more of those locations to the existing financial ecosystem. That means more choice about where customers access live data and run applications, including AI inference, while improving synchronicity between market centers."

Commercial inquiries: [email protected]

About McKay Brothers

McKay Brothers, LLC provides purpose-built connectivity for global financial markets. Its wireless and wired networks connect major trading venues and data centers. McKay offers its services on an equal access basis, helping level the playing field and improve synchronicity across markets. Learn more at mckay-brothers.com.

About Relativity Networks

Relativity Networks builds advanced optical networking technology for the world's most latency-sensitive applications. At its core is the company's patented ChronoCore⢠hollow-core fiber, which enables data to travel roughly 47 percent faster than through conventional glass fiber, dramatically reducing network latency.

ChronoCore⢠reduces the time it takes data to travel between trading venues, exchanges and data centers, providing a significant advantage in markets where every microsecond matters. ChronoCore⢠also gives AI and data-center operators greater flexibility to locate compute where power is available, while reducing the latency penalties created by distance.

Designed to integrate with existing network infrastructure, ChronoCore⢠provides a practical path to higher-performance networks without requiring a wholesale redesign of the systems around them.

Learn more at www.relativitynetworks.ai.

SOURCE McKay Brothers, LLC

Share this article

Keeper recognized across government security, AI agent identity, privileged access management and quantum-resilient encryption, with its CEO, CTO and CISO also named winners

CHICAGO, Nov. 2, 2026 /PRNewswire/ -- Keeper Security, the leading zero-trust and zero-knowledge identity security platform, secured seven top honors in Cyber Defense Magazine's 2026 Top InfoSec Innovators Awards, underscoring the company's aggressive push to secure customers against emerging AI and quantum computing risks.

Top InfoSec Innovator Awards, Presented by Cyber Defense Magazine:

Next-Gen Cybersecurity for the Government

Most Innovative Identity Management for AI Agents

Hot Company Privileged Access Management (PAM)

Pioneering Quantum Resilient Encryption

Pioneering Cybersecurity Visionary: Darren Guccione, CEO and Co-founder

Trailblazing Chief Technology Officer: Craig Lurey, CTO and Co-founder

Trailblazing Chief Information Security Officer: Shane Barney, CISO

"We recognize global cybersecurity innovators that are helping to turn the tide against the exponential growth in cybercrime," said Yan Ross, Editor of Cyber Defense Magazine. "We are pleased to recognize Keeper Security and its leadership team in these coveted awards."

The accolades recognize not only Keeper's technical advancements, but the executive vision driving them. Guided by award-winners Guccione, Lurey and Barney, the company is rapidly expanding its zero-trust, zero-knowledge security architecture to protect the world's most complex and highly regulated enterprise environments. This includes advancing core PAM capabilities, such as KeeperAI, which automatically identifies and terminates high-risk privileged sessions in real-time, as well as maintaining the highest levels of public sector security with FedRAMP High Certification and GovRAMP High Authorization.

Beyond traditional access controls, Keeper is proactively defending against future threats. The Keeper AI Agent Kit brings autonomous systems and Model Context Protocol servers under the same strict governance as human users. To protect this expanding digital ecosystem, Keeper engineered a crypto-agile architecture to address evolving cryptographic threats. By layering NIST-standardized Kyber encryption over the elliptic curve cryptography that defends against today's threats, Keeper ensures long-term resilience by allowing the platform to rapidly swap algorithms if new quantum vulnerabilities emerge.

"The cybersecurity industry is undergoing the most disruptive shift we've ever seen," said Guccione. "The explosion of AI agents is forcing organizations to defend themselves at machine speed, while the threat of quantum decryption requires a complete rethink of how organizations must protect their data. You simply can't fight those battles with legacy tools. Taking home these awards reinforces that we are solving the right problems and delivering the architecture organizations need to protect themselves both now, and in the future."

To learn more about Keeper, visit keepersecurity.com.

About Keeper Security

Keeper Security is the leading zero-trust and zero-knowledge identity security solution, trusted by millions of people and thousands of organizations globally. KeeperPAM® is Keeper's privileged access management platform that unifies password and passkey management, secrets management, privileged session management and endpoint privilege management in a single cloud-native platform, protected with quantum-resistant encryption. KeeperAI® delivers real-time, AI-native threat detection across every privileged session. As AI agents proliferate and identity becomes the defining attack surface, Keeper governs access for humans, machines, non-human identities and AI agents, serving as the unified control plane for access, compliance and visibility across the enterprise. For more information, visit KeeperSecurity.com.

Learn more: KeeperSecurity.com

Follow Keeper: Facebook Instagram LinkedIn X YouTube TikTok

Media Contact

Katherine Benfield

ICR for Keeper Security

[email protected] 

SOURCE Keeper Security

Share this article

CLEVELAND, Nov. 2, 2026 /PRNewswire/ -- Over 100 Portland DMA schools are participating in the KOIN-led movement to provide coverage for every high school activity through its partnership with DistrictWON's uReport. That movement has been supercharged. uReport has been awarded the ISTE Seal, a validation program that recognizes high-quality educational technology solutions.

uReport is a digital platform that helps schools create and share stories about their students, teams, activities, and communities.

It now opens endless possibilities to energize curriculum and excite students with real-world training and experience in technology, journalism, media and more. Additionally, it provides measurable outcomes to the community through positive stories of activities and student achievements previously unseen.

"The ISTE Seal is the gold standard that very few companies have achieved. What other classroom project has the power to create this much positive change?" says Peter Fitzpatrick, CEO of uReport.

Recognition Based on Three Principles

To earn the ISTE Seal, uReport underwent evaluation by a panel of experts in education and technology. The review assessed the platform across three principles:

- Alignment with the ISTE Standards: uReport was evaluated for alignment with the ISTE Standards for educational technology.

- Practical Usability: Reviewers assessed the platform's user-friendliness and learning design, including how easily educators and students can navigate and use its features.

- Digital Pedagogical Implementation: Reviewers evaluated how uReport supports the effective use of digital technology in educational settings.

Supporting School Storytelling

Through uReport, schools can publish and share stories that bring greater visibility to student experiences and school programs. The platform gives educators, staff, and authorized student contributors tools to create content and share it with their communities.

Here is the uReport listing in the ISTE Edtech Index: uReport - EdTech Index

Here is the uReport ISTE Findings Report: uReport - ISTE Findings Report

For any information, administrators can contact Dan McGrath, uReport's Director of Customer Success at [email protected] or direct at 216-282-1683 ext 216.

SOURCE DistrictWON

Share this article

Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity

SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that two abstracts highlighting new preclinical and translational research on paxalisib's differentiated biological activity and potential application across breast cancer settings have been accepted for poster presentation at this year's San Antonio Breast Cancer Symposium ("SABCS"), taking place on Dec. 8 through 11, 2026, in San Antonio, Texas.

The presentations will explore two complementary areas of research: the distinct tumor and immune reprogramming effects of paxalisib compared with other dual PI3K/mTOR inhibitors in preclinical models, and its potential to suppress local recurrence and metastatic progression when administered following standard neoadjuvant chemo-immunotherapy in a preclinical model of stage III triple-negative breast cancer (TNBC):

- Poster 1 (P4-9-18): "Paxalisib uniquely induces durable tumour and immune reprogramming across breast cancer subtypes, challenging the paradigm that dual PI3K/mTOR inhibitors are biologically equivalent"

- Poster 2 (P4-10-26): "Suppression of Local and Metastatic Recurrence by Adjuvant PI3K/mTOR Inhibition Through Durable Immune Epigenetic Rewiring Following Neoadjuvant Chemo-Immunotherapy in Stage III Triple-Negative Breast Cancer"

The research further explores paxalisib's differentiated ability to reprogram tumor and immune biology in preclinical models, suggesting that these effects are not necessarily shared by other dual PI3K/mTOR inhibitors. Kazia believes this emerging evidence supports a mechanism of action that extends beyond conventional kinase inhibition.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance. Kazia's lead asset, paxalisib, is an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed across multiple forms of cancer, including cancers of the central nervous system, advanced breast cancer and colorectal cancer. Paxalisib has received U.S. FDA Fast Track and Orphan Drug designations for glioblastoma, Fast Track designation for PI3K-altered brain metastases with radiation and Rare Pediatric Disease and Orphan Drug designations for select pediatric brain tumors, including diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumor.

Kazia is also advancing two potentially first-in-class preclinical programs: NDL2, a nuclear PD-L1 protein degrader targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, and MSETC, a SETDB1 inhibitor intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Additionally, Kazia's portfolio includes EVT801, a small molecule VEGFR-3 inhibitor that the Company is exploring for potential partnering opportunities. For more information, visit www.kaziatx.com, as well as follow us on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as "anticipates," "believes," "expects," "intends," "plans," "may," "will," "could," "should," "estimates," "projects," "potential," "suggests," and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: the timing and content of the Company's poster presentations at the 2026 San Antonio Breast Cancer Symposium; the potential of paxalisib to reprogram tumor and immune biology and to suppress local recurrence and metastatic progression; the potential differentiation of paxalisib from other PI3K/mTOR inhibitors; the Company's beliefs regarding paxalisib's mechanism of action; the potential application of paxalisib across breast cancer settings, including early-stage TNBC; and the Company's development plans for paxalisib.

These forward-looking statements are based on management's current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the risk that results of preclinical and translational studies may not be predictive of results in clinical trials in humans; the preliminary nature of early-stage data; risks associated with the research and development of therapeutic programs; the timing, conduct and enrollment of clinical trials; regulatory review and approval processes; the Company's ability to obtain sufficient funding to advance its programs; reliance on third-party collaborators, contract research organizations and trial sites; the Company's ability to obtain, maintain and protect its intellectual property; competition; general economic and market conditions; and the Company's ability to maintain compliance with Nasdaq listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company's filings with the SEC, including the "Risk Factors" section of the Company's most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

All forward-looking statements are qualified in their entirety by this cautionary statement.

SOURCE Kazia Therapeutics Limited

Share this article

In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's RHB-104 in both long-term intracellular culture and spot and phage assays

The two sets of studies, showing confirmed MAP-killing effect and comparability to RHB-104, led by Professor Tim Bull from City St George's University of London, and Prof Irene Grant, Professor of Microbiology and Food Safety, Queen's University Belfast and Dr Hannah Dane, further support development of RHB-204's potential in MAP-related Crohn's disease

In its positive Phase 3 study, RHB-104 met the primary endpoint with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone in treating Crohn's disease, compared to the placebo (standard of care only) group (p = 0.0048)1

RHB-2042, a proprietary next-generation oral optimized formulation of RHB-1043, designed for reduced toxicity and side effects and enhanced patient adherence, employs a differentiated, MAP-targeted approach to the treatment of Crohn's disease

RALEIGH, N.C. and TEL AVIV, Israel, Nov. 2, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the confirmation of RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP), and RHB-204's comparability to RHB-104 MAP-killing, following two sets of in vitro studies, undertaken by leading microbiology centers, in both long-term intracellular culture and spot and phage assays.

The two sets of studies led by Professor Tim Bull from City St George's University of London, and Prof Irene Grant, Professor of Microbiology and Food Safety, Queen's University Belfast and Dr Hannah Dane, support the potential for RHB-204's role in MAP-related Crohn's disease (CD) through demonstrated RHB-204 comparability to RedHill's RHB-104, which met the primary endpoint with statistical significance of its positive Phase 3 clinical trial, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048).

In vitro studies, undertaken by Professor Tim Bull, confirm RHB-204's MAP-killing capability MAP in long term intracellular culture4 and further demonstrate RHB-204's comparability to RedHill's RHB-104's MAP-killing effect. The positive results were seen across a range of MAP strains, taken from both human Crohn's disease patients and animal carriers of Johne's disease, sometimes referred to as "animal Crohn's", which were suggestive of both potential human and veterinary utility. The studies also showed that RHB-204 did not induce tolerance in the strains during the short exposure periods used in the studies (6 days max), suggesting that further consecutive dosing could add to the effect.

Tim Bull, Professor of Cell and Molecular Biology at City St George's University of London said: "RHB-204 demonstrated a significant MAP-killing effect, similar to RHB-104, against multiple strains of MAP, both human and animal, whilst intracellularly persistent. MAP is remarkably difficult to kill and test against due to its unique biological structure, intracellular lifestyle, and slow growth rate. This data gives a valuable insight into the potential of RHB-204 to treat MAP-related Crohn's disease involving either human or animal derived MAP strains."

Prof. Bull's work adds to the in vitro work undertaken by Rapid-myco Technologies, a world leader in the field and developer of a transformative diagnostic platform for the rapid detection of important and often life-threatening mycobacterial infections of humans and livestock. This work, led by Prof Irene Grant, Professor of Microbiology and Food Safety at Queen's University Belfast and Dr Hannah Dane, showed in vitro that RHB-204 demonstrated comparable MAP killing to RHB-104 in both spot and phage assays. Importantly, MAP killing efficacy was achieved with lower doses of two of the active ingredients compared to RHB-104, indicative of potential for reduced toxicity and side effects5.

"We know from previous published positive Phase 3 clinical testing that RHB-104 delivered a statistically significant 64% improvement over placebo in efficacy in treating Crohn's disease using a MAP-targeted approach. In vitro confirmation of RHB-204's MAP-killing effect and comparability to RHB-104 is another step forward in the development of RHB-204 for MAP-related CD," said Reza Fathi, PhD, Senior VP, R&D at RedHill. "We believe Phase 2-ready RHB-204 could be among the first treatments to be evaluated in an adequately controlled study in a specifically defined MAP-positive Crohn's disease patient population."

There is a significant body of peer reviewed published research supporting the scientific rationale that MAP may be a root cause of CD6, however, a major hurdle in previous clinical studies for new therapies directed at MAP has been the ability to rapidly and accurately detect MAP, one of the slowest growing and hardest to detect bacteria known.

We believe that RedHill's existing collaborations for the provision of cutting-edge MAP detection diagnostics, with two leading European research organizations, may provide the right conditions for a well-designed study in a specifically defined MAP-positive Crohn's disease patient population. Such a study could provide key evidence that could transform CD management and, if RHB-204 is approved, support a therapy addressing both the suspected cause of the disease and its symptoms.

New safe and effective orally administered therapeutic approaches are needed to help improve outcomes in the treatment of Crohn's disease. Up to 40% of CD patients fail to respond to anti-TNF treatment, and over time a similar proportion of responders lose response and have disease flare-ups7. Many existing treatment options are both expensive and intravenously administered, further increasing the cost burden. Moreover, several of these existing therapies have known safety issues, including Black Box Warnings. The CD market is expected to expand significantly, with sales in the United States, Japan, and five major European markets expected to grow at a compound annual growth rate (CAGR) of 3.87% to $19.1 billion by 20335.

RHB-204 is patent protected through 2041 and has been granted FDA Fast Track, Orphan Drug and QIDP and EU Orphan designations. Where applicable, the Company intends to explore the potential for additional designations, including FDA breakthrough therapy and pediatric orphan drug designations, which may provide a potential avenue for receiving a priority review voucher (PRV).

RedHill is actively pursuing partnerships and collaborations for this program, including through innovation development grant applications.

About RHB-204

RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin and clofazimine, at specific doses designed to safely and effectively treat Mycobacterium avium subspecies paratuberculosis-positive (MAP-positive)-related Crohn's disease.

RHB-204 is a next-generation formulation of RHB-104 with an optimized formulation for the treatment of CD. It contains the same three antimicrobial agents with potent intracellular, anti-mycobacterial and anti-inflammatory properties, and with an optimized dosing profile, RHB-204 provides the potential for enhanced tolerability, safety and compliance with a 40% pill burden reduction. RHB-204 is supported by clinical data from the positive safety and efficacy results achieved in the Phase 3 clinical study of RHB-104 in CD8, with its potential further demonstrated using mucosal healing imaging, which is widely used in the evaluation of efficacy in CD.

Originally developed for the treatment of pulmonary non-tuberculous mycobacteria (NTM) disease caused by Mycobacterium avium complex (MAC), RHB-204 was granted FDA Fast Track and Orphan Drug Designation, in addition to QIDP Designation under the Generating Antibiotic Incentives Now Act (GAIN Act), extending U.S. post-approval U.S. market exclusivity to a potential total of 12 years. RHB-204 has additionally been granted EU Orphan Designation, providing eligibility for 10 years EU post-approval market exclusivity.

About Crohn's Disease

Crohn's disease (CD) is a form of Inflammatory Bowel Disease (IBD) causing inflammation of digestive tract tissue that can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. CD can be highly debilitating and remains a serious burden for both patients and healthcare systems: significantly impairing quality of life and, in some cases, leading to life-threatening complications. There is no known cure for Crohn's disease. It is estimated that 1 million Americans9 and approximately 6-8 million people globally have Crohn's disease10.

Commonly used FDA-approved therapies in the treatment of CD include: Abbvie's Humira® (adalimumab), Janssen's Remicade® (infliximab) and Stelara® (Ustekinumab), BMS's Zeposia® (ozanimod) and Pfizer's Xeljanz® (tofacitinib).

About RedHill Biopharma

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a U.S. specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota®, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq®. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory, antiviral and metabolic activity, targeting multiple indications with a track record of U.S.

Aiper Black Friday Deals: passende Poolpflege bis zu 35 Prozent rabattiert

München (ots)

Smarte Lösungen für eine einfachere Poolpflege - als Geschenk für die Liebsten oder den eigenen Pool

Aiper, die Nr. 1 Marke für intelligente Roboter-Poolreiniger, gemessen am Absatzvolumen[1], gibt einen ersten Einblick auf seinen Black-Friday-Sale. Vom 19. November bis 1. Dezember 2026 können Interessierte ausgewählte Produkte im offiziellen Aiper-Store zu reduzierten Preisen erwerben. Zu den Highlights zählen der Scuba V3 für 849 EUR, das Experts Duo für 1.198 EUR und der Scuba S1 für 494 EUR.

Die Vorweihnachtszeit bietet Poolbesitzer:innen die Gelegenheit, sich mit der Anschaffung neuer Reinigungslösungen zu beschäftigen. Sei es für den eigenen Pool oder als praktisches Geschenk für Familie und Freunde. Dabei unterscheiden sich die Anforderungen je nach Pool und individuellen Bedürfnissen: Ob eine intelligente Reinigung sowohl unter als auch an der Wasseroberfläche oder eine zuverlässige und preisgünstige Lösung für den täglichen Einsatz. Im Rahmen der Black Friday Deals bietet Aiper verschiedene Modelle für diese unterschiedlichen Anforderungen rabattiert an.

Aiper Scuba V3: Ein smarterer Ansatz für die tägliche Poolpflege

Für Poolbesitzer, die den Aufwand für die Planung und Organisation der regelmäßigen Poolreinigung reduzieren möchten, bietet der Scuba V3 verschiedene KI-gestützte Funktionen. Der kognitive KI-Modus Navium(TM) erstellt Reinigungspläne auf Basis von Poolgröße, Wetter und Reinigungshistorie und passt die Reinigung so an die jeweiligen Gegebenheiten an. Die "AI Patrol Cleaning"-Funktion erkennt Verschmutzungen gezielt und ermöglicht eine bis zu zehnmal schnellerer Reinigung. Gleichzeitig sorgt die adaptive Routenplanung VisionPath(TM) für eine systematische Navigation durch den Pool. Der Scuba V3 reinigt Boden, Wände und Wasserlinie und bietet eine Wasserlinien-Rückholfunktion sowie Echtzeit-Benachrichtigungen über die App, welche die Entnahme des Geräts nach Abschluss der Reinigung erleichtern.

Zur Black-Friday-Aktion ist der Scuba V3 für 849 EUR statt 999 EUR im Aiper-Store erhältlich (150 EUR Rabatt).

Aiper Experts Duo: Zwei Experten, sorgenfreie Poolpflege rund um die Uhr

Für Poolbesitzer, die sowohl Verschmutzungen an der Wasseroberfläche als auch unter Wasser entfernen möchten, kombiniert das Experts Duo den Scuba V3 und den Roboter-Pool-Skimmer EcoSurfer S2 in einer Lösung. Während sich der Scuba V3 um Boden, Wände und Wasserlinie kümmert, sammelt der EcoSurfer S2 Verschmutzungen - beispielsweise schwimmende Blätter - auf der Wasseroberfläche ein. Dank des solarbetriebenen Antriebs und der SolarSeeker(TM)-Technologie ist eine kontinuierliche Oberflächenreinigung möglich, sodass Verschmutzungen entfernt werden können, bevor sie sich auf am Boden absetzen. Gemeinsam decken die beiden Roboter verschiedene Reinigungsbereiche ab und ergänzen sich bei der automatisierten Poolpflege.

Während der Black-Friday-Aktion ist das Experts Duo um 100 EUR reduziert, auf 1.198 EUR statt 1.298 EUR.

Aiper Scuba S1: Tägliche Reinigung, praktischer Vorteil

Für Poolbesitzer, die erstmals auf eine automatisierte Poolreinigung umsteigen oder ihre bestehende Ausstattung kostengünstig ergänzen möchte, bietet der Scuba S1 mit seinen verschiedene Reinigungsfunktionen die perfekte Lösung. Der Roboter reinigt Boden, Wände und Wasserlinie und nutzt die WavePath(TM) 2.0-Navigation für eine systematische Routenplanung. Die ultrafeine MicroMesh(TM)-Filterung ermöglicht es, auch feine Schmutzpartikel aufzufangen.

Im Rahmen der Black-Friday-Aktion ist der Scuba S1 von 599 EUR auf 494 EUR zu einem Rabatt von 105 EUR im Aiper-Store reduziert.

Erste Angebote und exklusive Vorteile vor dem Black Friday

Aiper startet bereits am 2. November 2026 mit den ersten Pre-Black-Friday-Aktionen. Darunter Vorverkaufsvorteile und exklusive Angebote für Mitglieder, die bereits vor dem Hauptereignis starten. Die Aktion geht vom 19. November bis zum 1. Dezember weiter - mit Black-Friday-Rabatten von bis zu 35 Prozent auf ausgewählte Produkte im offiziellen Aiper-Store.

Alle Angebote im Überblick

Black Friday - Aiper Store (19. November - 1. Dezember)

Produkt | UVP | Aktionspreis | Differenz | Rabatt

Scuba V3 | 999 EUR | 849 EUR | 150 EUR | 15 %

Scuba S1 | 599 EUR | 494 EUR | 105 EUR | 18 %

IrriSense 2 | 499 EUR | 399 EUR | 100 EUR | 20 %

Aiper Experts Duo | 1.298 EUR | 1.198 EUR |100 EUR | 8 %

Zusätzliche Angebote auf Amazon (19. November - 1. Dezember)

Produkt | UVP | Aktionspreis | Differenz | Rabatt

Scuba V3 | 1.099 EUR | 849 EUR | 250 EUR | 23 %

EcoSurfer S2 | 399 EUR | 339 EUR | 60 EUR | 15 %

IrriSense 2 | 599 EUR | 399 EUR | 200 EUR | 33 %

Scuba S1 | 699 EUR | 494 EUR | 205 EUR | 29 %

Scuba S3 | 749 EUR | 599 EUR | 150 EUR | 20 %

Scuba X1 Pro Max | 1.999 EUR | 1.699 EUR | 300 EUR | 15 %

Aiper Seagull 800B | 179 EUR | 149 EUR | 30 EUR | 22 %

Scuba SE | 149 EUR | 139 EUR | 10 EUR | 7 %

[1] Quelle: Euromonitor International Co. Ltd., bezogen auf das weltweite Hersteller-Verkaufsvolumen (Stück) im Jahr 2025. Intelligente Roboter-Poolreiniger sind definiert als intelligente Serviceroboter, die mechanische, elektronische, Software-Algorithmus- und Sensortechnologien integrieren. Sie führen autonom oder mit minimalem menschlichem Eingriff Poolreinigungs- und Wartungsaufgaben durch und verfügen in der Regel über intelligente Navigation, Wegplanung und mehrere Reinigungsmodi. Die Studie wurde im März 2026 abgeschlossen.

Pressekontakt:

Marike Labus, Inka Kristen Wolf, Alexander Seiche

Sendlinger Straße 42 A

D-80331 München

Tel: +49 (0)89 211871 -53/ -76 / -37

E-Mail: aiper@schwartzpr.de

www.schwartzpr.de

Original-Content von: Aiper, übermittelt durch news aktuell